Ito Mamoru, Kusaba Hitoshi, Mukaide Satomi, Kishimoto Junji, Shimokawa Hozumi, Tamura Shingo, Makiyama Akitaka, Hirano Gen, Oda Hisanobu, Shirakawa Tsuyoshi, Komoda Masato, Uchino Keita, Tanaka Risa, Mitsugi Kenji, Esaki Taito, Arita Shuji, Ariyama Hiroshi, Akashi Koichi, Baba Eishi
aDepartment of Hematology and Oncology bCenter for Clinical and Translational Research cDepartment of Research and Development of Next Generation Medicine, Faculty of Medical Science, Kyushu University Hospital dDepartment of Medical Oncology, National Hospital Organization, Kyushu Medical Center eDepartment of Hematology and Oncology, Japan Community Health Care Organization Kyushu Hospital fDepartment of Medical Oncology, Saiseikai Fukuoka General Hospital gDepartment of Medical Oncology, Fukuoka Wajiro Hospital hDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center iDepartment of Medical Oncology, Hamanomachi Hospital jDepartment of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka kDepartment of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan.
Anticancer Drugs. 2017 Nov;28(10):1166-1173. doi: 10.1097/CAD.0000000000000562.
A close correlation between early tumor shrinkage (ETS) and overall survival (OS) has been shown in antiepidermal growth factor receptor antibody-based chemotherapies for metastatic colorectal cancer (mCRC), but the clinical impact of ETS in bevacizumab-based chemotherapy has not been adequately clarified. Clinical data of mCRC patients who started initial chemotherapy without antiepidermal growth factor receptor antibody from 2005 to 2010 were retrospectively evaluated. The relative change in tumor size after 8 weeks of chemotherapy expected from the first image assessment [estimated ETS (EETS)] and the relative change in the tumor size at the nadir compared with the baseline [depth of response (DPR)] were examined. Seventy-three patients were enrolled and 61 patients were evaluable for survival by simple regression analysis. Bevacizumab-based chemotherapies were administered to 40 (66%) patients. The median EETS, DPR, progression-free survival, and OS were 16.1%, 27.2%, 8.0 months, and 19.5 months, respectively. Progression-free survival showed a positive correlation with OS (R=0.429), whereas EETS and DPR were less correlated with OS (R=0.0682, 0.186). EETS was well correlated with DPR (R=0.659). Patients with EETS greater than 16.12% were predicted to achieve tumor shrinkage of more than 30% at the maximum response. EETS in bevacizumab-treated mCRC showed a close correlation with DPR, which suggested that EETS might be useful, indicating a favorable response in treatment with bevacizumab-based chemotherapy.
在基于抗表皮生长因子受体抗体的转移性结直肠癌（mCRC）化疗中，已显示早期肿瘤缩小（ETS）与总生存期（OS）密切相关，但ETS在基于贝伐单抗的化疗中的临床影响尚未得到充分阐明。对2005年至2010年开始初始化疗且未使用抗表皮生长因子受体抗体的mCRC患者的临床数据进行回顾性评估。检查了首次影像评估预期的化疗8周后肿瘤大小的相对变化[估计ETS（EETS）]以及与基线相比最低点时肿瘤大小的相对变化[缓解深度（DPR）]。共纳入73例患者，通过简单回归分析，61例患者可评估生存期。40例（66%）患者接受了基于贝伐单抗的化疗。EETS、DPR、无进展生存期和OS的中位数分别为16.1%、27.2%、8.0个月和19.5个月。无进展生存期与OS呈正相关（R=0.429），而EETS和DPR与OS的相关性较小（R=0.0682，0.186）。EETS与DPR相关性良好（R=0.659）。EETS大于16.12%的患者预计在最大缓解时肿瘤缩小超过30%。贝伐单抗治疗的mCRC患者的EETS与DPR密切相关，这表明EETS可能有用，提示基于贝伐单抗的化疗治疗反应良好。
